Eiger BioPharmaceuticals Inc

NASDAQ:EIGR   3:59:55 PM EDT
10.17
+0.03 (+0.30%)
Earnings Announcements

Eiger Announces Results Of Investigator Sponsored Study In Outpatients With Mild And Uncomplicated Covid-19

Published: 09/28/2020 12:23 GMT
Eiger BioPharmaceuticals Inc (EIGR) - Eiger Announces Results of Investigator Sponsored Study in Outpatients With Mild and Uncomplicated Covid-19.
Eiger Biopharmaceuticals - No Difference Was Demonstrated in Duration of Sars-cov-2 Viral Shedding and Time to Symptom Resolution Versus Placebo.
Eiger Biopharmaceuticals Inc - Lambda Was Well-tolerated With Few Adverse Events, Which Included Elevated Transaminases Which Self-resolved.
Revenue is expected to be $2 Million
Adjusted EPS is expected to be -$0.61

Next Quarter Revenue Guidance is expected to be $0.18 Million
Next Quarter EPS Guidance is expected to be $0.87

More details on our Analysts Page.